1. Home
  2. BEAM vs BELFB Comparison

BEAM vs BELFB Comparison

Compare BEAM & BELFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$28.62

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Bel Fuse Inc. Class B

BELFB

Bel Fuse Inc. Class B

HOLD

Current Price

$258.71

Market Cap

3.5B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
BELFB
Founded
2017
1949
Country
United States
United States
Employees
N/A
4964
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.5B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
BELFB
Price
$28.62
$258.71
Analyst Decision
Buy
Strong Buy
Analyst Count
12
4
Target Price
$50.75
$174.25
AVG Volume (30 Days)
1.9M
208.1K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
0.11%
EPS Growth
82.31
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$9.74
Revenue Next Year
$33.77
$6.34
P/E Ratio
N/A
$42.80
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$70.87
52 Week High
$36.44
$308.27

Technical Indicators

Market Signals
Indicator
BEAM
BELFB
Relative Strength Index (RSI) 45.77 46.29
Support Level $28.50 $241.14
Resistance Level $29.06 N/A
Average True Range (ATR) 2.02 15.43
MACD -0.31 -4.19
Stochastic Oscillator 5.27 22.85

Price Performance

Historical Comparison
BEAM
BELFB

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About BELFB Bel Fuse Inc. Class B

Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.

Share on Social Networks: